Table 3.
Association Between MRA Prescription Within 3 Months and Selected Variables Among 126 MRA‐Eligible Patients With STEMI Not Prescribed an MRA at Discharge
| No MRA (n=114) | MRA (n=12) | P Value | |
|---|---|---|---|
| LVEF, median (IQR), % |
40.0 (35.0–49.0) n=43 |
32.5 (30.0–33.0) n=5 |
0.042 |
| Modified congestion score†, n (%) | 0.289 | ||
| 0 | 92 (80.7) | 10 (83.3) | |
| 1 | 16 (14.0) | 1 (8.3) | |
| 2 | 5 (4.4) | 0 | |
| 3 | 1 (0.9) | 1 (8.3) | |
| Serum potassium | |||
| Median (IQR), mmol/L |
4.4 (4.1–4.7) n=35 |
3.5 (–) n=1 |
0.091 |
| >5.5 mmol/L | n=0 | n=0 | … |
| Serum creatinine, median (IQR), µmol/L |
94.0 (82.0–118.0) n=39 |
99.5 (87.0–112.0) n=2 |
1.000 |
IQR indicates interquartile range; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; and STEMI, ST‐segment–elevation myocardial infarction.
†
Range 0 to 3 based on presence of jugular venous pressure elevation, crackles, and peripheral edema.